Benzinga · Aug 28, 2026
FDA Approves Stelara for Pediatric Ulcerative Colitis
https://www.fda.gov/drugs/news-events-human-drugs/fda-approves-stelara-pediatric-ulcerative-colitis
NYSE · JNJ
Johnson & Johnson
Healthcare · Drug Manufacturers - General
$268.04
Up+$2.27 (+0.85%)
Updated Aug 31, 2026, 6:55 AM
SID Score
7.8/10
Composite research score
Smart Money
56/100
Neutral
- Market cap
- 505.78B
- P/E ratio
- 20.3
- Dividend yield
- 1.92%
- 52-week range
- $199.91 – $276.47
- Volume
- 5.77M
- Avg. volume
- 8.82M
Price performance
JNJ price history
1M range · 20 trading sessions · Daily adjusted prices
JNJ closed at $268.04 after 20 trading sessions, up 5.36% for the selected period.
- Last close
- $268.04
- Period change
- +5.36%
- Period low
- $254.41
- Period high
- $273.41
Daily close
View OHLC price history
| Date | Open | High | Low | Close | Volume |
|---|---|---|---|---|---|
| Aug 28, 2026 | $265.78 | $268.38 | $264.27 | $268.04 | 5.77M |
| Aug 27, 2026 | $268.45 | $268.45 | $263.83 | $265.77 | 7.31M |
| Aug 26, 2026 | $271.97 | $272.905 | $269.55 | $270.00 | 7.22M |
| Aug 25, 2026 | $271.00 | $273.8021 | $270.175 | $273.14 | 4.69M |
| Aug 24, 2026 | $269.74 | $273.98 | $268.57 | $273.04 | 5.44M |
| Aug 21, 2026 | $267.83 | $272.655 | $267.00 | $270.24 | 6.19M |
| Aug 20, 2026 | $273.40 | $273.40 | $267.37 | $267.37 | 6.48M |
| Aug 19, 2026 | $272.995 | $276.47 | $270.56 | $273.41 | 7.73M |
| Aug 18, 2026 | $267.67 | $271.73 | $266.33 | $271.11 | 7.84M |
| Aug 17, 2026 | $258.87 | $264.2775 | $258.01 | $262.37 | 5.52M |
| Aug 14, 2026 | $260.65 | $261.71 | $259.16 | $260.35 | 5M |
| Aug 13, 2026 | $261.725 | $262.62 | $259.6475 | $262.08 | 4.85M |
| Aug 12, 2026 | $256.00 | $261.41 | $255.255 | $260.86 | 4.63M |
| Aug 11, 2026 | $261.23 | $264.15 | $258.36 | $259.80 | 5.95M |
| Aug 10, 2026 | $259.06 | $262.00 | $258.55 | $261.81 | 8.99M |
| Aug 7, 2026 | $255.89 | $259.60 | $255.12 | $259.24 | 6.53M |
| Aug 6, 2026 | $261.71 | $262.11 | $255.28 | $256.98 | 6.93M |
| Aug 5, 2026 | $255.25 | $259.32 | $254.47 | $257.59 | 6.47M |
| Aug 4, 2026 | $254.41 | $255.52 | $250.44 | $254.93 | 7.36M |
| Aug 3, 2026 | $254.97 | $257.75 | $250.91 | $254.41 | 8.14M |
Latest JNJ news
The latest Smart Investors Daily articles mentioning JNJ.
Stock researchCompany · Overview
JNJ research
Overview
Company profile and research snapshot.
Company profile
Johnson & Johnson is the world's largest and most diverse healthcare firm. It has two divisions: innovative medicine and medtech. These now represent all of the company's sales following the divestment of the consumer business, Kenvue, in 2023. After restructurings in 2023-24, the drug division focuses on three main therapeutic areas: immunology, oncology, and neurology. Geographically, just over half of total revenue is generated in the United States.
Visit company websiteAnalyst outlook
Consensus and target data currently published for this company.
- Consensus
- Buy
- Average target
- $207.08
- Implied upside
- —
- Analysts
- 18
| Date | Firm | Rating | Target |
|---|---|---|---|
| Aug 6, 2026 | Guggenheim | Buy | — |
| Aug 3, 2026 | Wells Fargo | Overweight | — |
| Jul 17, 2026 | Guggenheim | Buy | — |
| Jul 16, 2026 | Wells Fargo | Overweight | — |
| Jul 16, 2026 | RBC Capital | Outperform | — |
News briefing
No generated briefing is available yet.
Benzinga · Aug 28, 2026
World Health Organization Director General Determined That The Ebola Epidemic In DRC Still Meets Criteria Of Public Health Emergency Of International Concern, But Not Those Of A Pandemic Emergency
https://www.who.int/news/item/28-08-2026-second-meeting-of-the-ihr-emergency-committee-on-the-epidemic-of-ebola-bundibugyo-virus-disease-in-the-democratic-republic-of-the-congo---meeting-report
SeekingAlpha · Aug 28, 2026
Best Dividend Aristocrats For September 2026
Dividend Aristocrats (NOBL) nearly match SPY in 2026, with top gainers, rising dividend growth, and 29 undervalued picksâsee which to buy now.
SeekingAlpha · Aug 27, 2026
GSK: Still One Of My Top Healthcare Picks
GSK stock outlook: FDA bepirovirsen Oct 26 decision, Phase 3 OCEAN results, and reaffirmed 2026 guidance. Read here for a detailed investment analysis.
AI research layers
Interpretive context generated from the platform’s current data sources.
Johnson & Johnson Stock Performance
Johnson & Johnson shares closed at $268.04, reflecting a modest intraday decline of 0.38%, per SID market data. Over the trailing twelve months, JNJ has appreciated 30.54%, significantly outpacing its historically defensive profile characterized by a beta of just 0.349. On a shorter horizon, the stock gained 4.78% over the past month and 18.95% over three months, indicating sustained upward momentum. Technical indicators confirm this trajectory, with the current price trading above both the 50-day moving average of $258.14 and the 200-day moving average of $240.33, according to Massive/Polygon data. The 14-day relative strength index stands at 57.7, positioning JNJ in neutral territory without overbought or oversold signals. Average daily trading volume registers at approximately 8.82 million shares, supporting adequate liquidity for institutional participation. The company's market capitalization currently stands at approximately $505.8 billion.
Johnson & Johnson Valuation Analysis
Johnson & Johnson currently trades at a price-to-earnings ratio of 20.30, per SID market data, positioning it within a moderate valuation range for large-cap healthcare companies. The PEG ratio stands at 1.91, suggesting the stock is trading near fair value relative to its expected earnings growth rate, according to SEC filings and consensus estimates. The price-to-book ratio of 6.43 reflects the market's premium on JNJ's extensive portfolio of pharmaceutical and medical device assets, including substantial intangible property. On the income return front, the company offers a dividend yield of 2.45%, consistent with its long-standing status as a Dividend Aristocrat. Within the healthcare sector, this yield provides a competitive income component for total return investors. The combination of a moderate P/E, near-parity PEG ratio, and steady dividend yield presents a balanced valuation profile that reflects both JNJ's defensive characteristics and its growth trajectory in key therapeutic areas.
Smart Money Activity for JNJ
Johnson & Johnson's composite smart money score registers at 56 out of 100, signaling a neutral overall positioning among sophisticated market participants, per SID market data. Institutional ownership scores a perfect 25 out of 25, reflecting robust conviction from large fund managers and asset allocators who continue to maintain significant positions in the stock. In contrast, the insider activity score stands at 8.6 out of 25, weighed down by mixed trading patterns. According to SEC Form 4 filings, there have been 19 insider transactions over the past 90 days, comprising 8 purchases and 11 sales, indicating a slight net selling bias among corporate officers and directors. Dark pool activity scores 9.5 out of 25, suggesting limited off-exchange accumulation at current price levels. Congressional trading activity registers at 13.2 out of 25, reflecting moderate interest from legislators disclosed in public filings. The divergence between strong institutional conviction and tepid insider buying warrants monitoring as a potential signal of differing internal and external sentiment.
Johnson & Johnson Earnings Outlook
Johnson & Johnson has demonstrated consistent earnings execution across its four most recent reporting periods, according to company earnings reports. In the most recent quarter reported on July 15, 2026, JNJ posted earnings per share of $2.90, exceeding the consensus analyst estimate of $2.85 by $0.05. The prior quarter, reported April 14, 2026, delivered EPS of $2.70 against estimates of $2.67, producing a positive surprise of $0.03. The January 2026 quarter showed a marginal miss, with actual EPS of $2.46 falling $0.01 below the $2.47 estimate. The September 2025 quarter produced EPS of $2.80, beating the $2.78 consensus by approximately $0.015. Across these four periods, JNJ achieved three beats and one narrow miss, reflecting stable operational performance. The sequential improvement from $2.46 to $2.90 in reported EPS demonstrates meaningful quarterly earnings growth, suggesting positive momentum in the company's pharmaceutical and MedTech segments.
Wall Street Analyst Ratings for JNJ
Wall Street coverage of Johnson & Johnson remains uniformly constructive, with recent analyst actions reaffirming positive outlooks, per SID consensus data. On August 6, 2026, Guggenheim reiterated its Buy rating on JNJ, maintaining conviction in the company's growth trajectory. Wells Fargo similarly reaffirmed its Overweight rating on August 3, 2026, sustaining its bullish stance from prior coverage. Earlier in July 2026, RBC Capital reiterated an Outperform rating, adding to the chorus of favorable assessments. Notably, none of the five most recent analyst actions involved a downgrade or initiation at a neutral or negative rating, according to Wall Street analyst reports. All ratings represent reiterations rather than upgrades, indicating that sell-side sentiment has remained stable and positive through recent quarters. The consistency across three separate firms — Guggenheim, Wells Fargo, and RBC Capital — spanning both main coverage and sector-specific research underscores broad institutional confidence in JNJ's fundamental positioning within the healthcare landscape.
